about
Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase.Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemiaThe oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesisPrevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patientsClinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution.Trends in management of acute lymphoblastic leukemia: Influence of insurance based healthcare and treatment compliance on the outcome of adolescents and adults with acute lymphoblastic leukemia.Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy.Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real worldEarly molecular response in chronic myeloid leukemia patients predicts future response status.Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.Current profile of hepatocellular carcinoma from a tertiary care center in Andhra Pradesh.Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.Renal Lymphoma: Primary or First Manifestation of Aggressive Pediatric B-cell Lymphoma.Primary intramedullary non-Hodgkin's lymphoma in an immunocompetent child.Temporal trends of splenectomy in pediatric hospitalizations with immune thrombocytopenia.Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014Temporal Trends of Pediatric Hospitalizations with Acute Disseminated Encephalomyelitis in the United States: An Analysis from 2006 to 2014 using National Inpatient SampleEpistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemiaGenetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL
P50
Q34538899-629B4664-E115-4292-8C91-AAD88EAD9E77Q34686255-A0B72643-3939-48F0-B28D-CC1281C063CDQ35172895-D1C13A26-9BEE-4773-B9A6-B8E5A23F2304Q36330709-227DB677-B10F-4324-A8F7-CCF25F64C2D7Q36458013-E27C83D3-D274-4201-A60B-1F8C2848AC84Q36696367-E4664667-4823-4250-A88B-4AA039DF2EBBQ37584918-3D267C55-DF27-4519-B515-6FA4AF036D35Q37584927-7A2F79A7-F53A-4583-94F4-BE33C2E6790EQ39274518-F4846FE2-7F12-4973-8F6C-5546E485EF24Q39934337-DA3A9B14-3752-41FB-9C2F-27F8BD143002Q44127621-AF2C745A-BD03-438D-BFB2-AEFFCBE6696AQ47147746-5ECBB2BE-C0D6-462B-AF57-9C54B4C193DDQ49195668-1DA4E6F1-6F9E-4683-9C47-762605BCE4C2Q50649895-F0F4C96F-9276-4CC9-BD8A-E6E087E1DB4EQ52720108-9A154621-2527-4DB1-8370-C2080F7A5CDFQ53235595-045F22F3-8269-40B9-87B2-5C9676E51BD7Q54357380-A15C98F1-F4B9-4EC9-8AA7-74F1606BCF64Q57175683-8C7F463C-9A9A-4419-A679-C272D0060109Q64386226-C1ED324F-3475-47F1-A0EA-FC7F7435DE3CQ82082980-D9AD54DB-826C-4E43-8F46-E5AE1219E6ACQ84638912-C9444B1E-28B9-4176-983E-50D0374B7604
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Vijay Gandhi Linga
@en
Vijay Gandhi Linga
@nl
type
label
Vijay Gandhi Linga
@en
Vijay Gandhi Linga
@nl
prefLabel
Vijay Gandhi Linga
@en
Vijay Gandhi Linga
@nl
P31
P496
0000-0001-8540-7296